Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
Phase 1
Terminated
- Conditions
- Non Hodgkin LymphomaSolid Tumor
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Adagene (Suzhou) Limited
- Target Recruit Count
- 25
- Registration Number
- NCT04775680
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Adagene (Suzhou) Limited
- Target Recruit Count
- 62
- Registration Number
- NCT03802955
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Shanghai Dongfang Hospital, Shanghai, Shanghai, China
News
No news found